Bare Metal Stent: Definition, Clinical Significance, and Overview

Posted on February 28, 2026 | by drheartcare

Bare Metal Stent Introduction (What it is)

A Bare Metal Stent is a small metal mesh tube placed inside a narrowed artery to help keep it open.
It is a device used in interventional cardiology, most commonly during percutaneous coronary intervention (PCI).
It is typically used to treat coronary artery disease (CAD) by improving blood flow in the coronary arteries.
It is distinct from a drug-eluting stent (DES), which releases medication to reduce tissue regrowth.

Clinical role and significance

Bare Metal Stent technology helped define modern coronary revascularization by reducing abrupt vessel closure after balloon angioplasty and improving immediate procedural success. In cardiology, it sits at the intersection of acute care (e.g., acute coronary syndrome) and long-term management (prevention of recurrent ischemia and complications).

Clinically, the key significance of a Bare Metal Stent is how it changes vessel healing. After implantation, the stent becomes incorporated into the vessel wall through endothelialization (growth of a cell layer over the metal struts). This healing process can stabilize the treated segment but can also drive neointimal hyperplasia (scar-like tissue growth), which is the main mechanism of in-stent restenosis. Compared with DES, Bare Metal Stent devices are generally associated with higher rates of restenosis, while the required duration of dual antiplatelet therapy (DAPT) has historically been shorter in many practice settings; exact recommendations vary by guideline era, patient bleeding risk, and local protocols.

Even where Bare Metal Stent use has declined with advances in DES, it remains an important concept for exams and clinical reasoning. Understanding Bare Metal Stent indications, limitations, and follow-up helps clinicians interpret cath lab histories, manage antiplatelet therapy discussions, and evaluate recurrent angina after PCI.

Indications / use cases

Typical scenarios where a Bare Metal Stent may be considered or encountered include:

PCI for symptomatic CAD when stenting is needed and device choice is being individualized
Situations where clinicians aim to minimize the required duration of DAPT (varies by clinician and case)
Treatment of focal coronary stenoses suitable for stent deployment (based on angiographic assessment)
Treatment of acute coronary syndrome (ACS), including ST-elevation myocardial infarction (STEMI) or non–ST-elevation ACS (NSTEMI/unstable angina), when PCI is performed and a Bare Metal Stent is selected
Settings where cost, availability, or institutional inventory affects device selection (varies by institution)
Cases where a prior Bare Metal Stent is present and the patient presents later with recurrent chest pain, suspected restenosis, or stent thrombosis

Contraindications / limitations

A Bare Metal Stent is not “contraindicated” in the same way as a medication, but there are important situations where it may be unsuitable or where alternatives may be preferred:

Inability to take antiplatelet therapy as required after stent implantation (risk of stent thrombosis)
Very small vessel diameter or diffuse long-segment disease, where restenosis risk is a concern and other strategies may be favored
Lesions with complex anatomy (e.g., some bifurcations, heavy calcification, tortuosity) where procedural success and long-term patency depend on technique and device choice
Patients with high predicted restenosis risk (e.g., diabetes mellitus, long lesion length), where DES is often considered (varies by clinician and case)
Situations where coronary artery bypass grafting (CABG) or optimized medical therapy is more appropriate based on overall coronary anatomy (e.g., left main or multivessel disease), ventricular function, and patient factors
When a non-stent approach is preferred for a specific lesion type (e.g., balloon angioplasty in select settings, atherectomy-assisted strategies, or drug-coated balloons in some territories; availability varies)

How it works (Mechanism / physiology)

A Bare Metal Stent works by providing a scaffold inside an artery. During PCI, the stent is expanded (typically with a balloon) to press atherosclerotic plaque and vessel wall outward, increasing lumen diameter and improving coronary blood flow.

Relevant anatomy and structures

Coronary arteries: epicardial vessels supplying the myocardium; stenosis can cause angina or myocardial infarction.
Endothelium and vessel wall layers: stent struts contact the intima and media; healing involves endothelialization.
Myocardium: downstream tissue affected by ischemia; symptom relief depends on restoring perfusion.

Onset, durability, and reversibility

Onset: mechanical lumen gain is immediate at deployment.
Durability: the stent remains permanently implanted; long-term patency depends on healing response, lesion characteristics, and risk factor control.
Key biological trade-off: the vessel’s healing response can cause neointimal hyperplasia, narrowing the stented segment (in-stent restenosis). This is usually a subacute-to-chronic process rather than immediate.
Thrombosis risk: until the stent is adequately endothelialized, the metal surface can promote platelet adhesion and thrombosis, which is why antiplatelet therapy is central to post-PCI management.

Bare Metal Stent Procedure or application overview

A Bare Metal Stent is applied as part of PCI in a cardiac catheterization laboratory. The specifics vary by operator, lesion complexity, and institutional protocol, but the general workflow is:

Evaluation / exam – Clinical assessment of chest pain syndromes (stable angina vs ACS) – Review of cardiovascular risk factors (e.g., hypertension, diabetes, smoking) and comorbidities (e.g., chronic kidney disease, bleeding risk)
Diagnostics – Electrocardiogram (ECG) and cardiac biomarkers when ACS is suspected – Noninvasive testing in selected stable patients (e.g., stress testing), depending on presentation – Coronary angiography to define coronary anatomy and lesion severity
– Adjunctive physiology or imaging may be used in some cases (e.g., fractional flow reserve [FFR], intravascular ultrasound [IVUS], optical coherence tomography [OCT])
Preparation – Antithrombotic strategy planning (antiplatelet and anticoagulation), tailored to bleeding and ischemic risks (varies by clinician and case) – Vascular access planning (radial or femoral approach) – Selection of stent size and length to match vessel dimensions
Intervention – Lesion crossing with a guidewire – Balloon angioplasty (predilation) when needed – Stent deployment and expansion – Postdilation and optimization may be performed to improve stent apposition and expansion (often guided by angiography and sometimes IVUS/OCT)
Immediate checks – Assessment of final angiographic result (flow, residual stenosis, dissection) – Monitoring for acute complications (ischemia, arrhythmia, access-site issues)
Follow-up / monitoring – Planning antiplatelet therapy duration and follow-up for symptoms – Risk factor modification and cardiac rehabilitation discussions (general principles; individualized plans vary)

Types / variations

Bare Metal Stent designs vary across manufacturers and generations. Common practical distinctions include:

Material
Stainless steel, cobalt-chromium, or other alloys (specific composition varies by device and era)
Strut thickness and architecture
Thinner-strut designs may improve deliverability and healing characteristics, while maintaining radial strength (trade-offs vary by device)
Delivery characteristics
Differences in flexibility, trackability, and radial force affect ease of placement in tortuous or calcified vessels
Coronary vs non-coronary use
“Bare metal” stents also exist in peripheral arterial disease contexts, but this overview focuses on coronary PCI where the term is most often tested and discussed
Clinical context
Primary PCI in STEMI vs elective PCI in stable ischemic heart disease (device selection considerations differ by scenario and evolving evidence)

Advantages and limitations

Advantages:

Provides immediate mechanical scaffolding and improved lumen diameter after angioplasty
Reduces risk of abrupt vessel closure compared with balloon angioplasty alone
Generally straightforward implantation within standard PCI workflows
Historically associated with shorter DAPT courses than earlier-generation DES in some protocols (practice varies by clinician and case)
No drug polymer/drug elution component, which can be relevant in discussions of device hypersensitivity (uncommon; clinical relevance varies)
Broad familiarity among cath lab teams due to long-standing use

Limitations:

Higher likelihood of in-stent restenosis compared with DES due to neointimal hyperplasia
Does not address the underlying systemic nature of atherosclerosis; ongoing CAD risk persists
Stent thrombosis remains a serious complication if antiplatelet therapy is interrupted or if implantation is suboptimal
Less favorable for long lesions, small vessels, or high-restenosis-risk phenotypes (e.g., diabetes), where DES is often considered
Metal artifact can affect some imaging interpretations and complicate future interventions at the same segment
Contemporary practice often favors newer-generation DES even when shorter DAPT is desired, depending on guidelines and patient factors (varies by clinician and case)

Follow-up, monitoring, and outcomes

Outcomes after Bare Metal Stent implantation depend on a combination of lesion-related, patient-related, and procedure-related factors. Important influences include the severity and distribution of CAD, the presence of diabetes mellitus or chronic kidney disease, smoking status, lipid control, and left ventricular function.

From a monitoring perspective, clinicians typically focus on:

Symptoms: recurrent exertional angina, reduced exercise tolerance, or new rest pain can suggest restenosis or progression of CAD elsewhere.
Medication adherence and tolerability: especially antiplatelet therapy, alongside guideline-directed medical therapy such as statins and antianginal agents (specific regimens vary).
Complications to recognize: in-stent restenosis (often presenting weeks to months later) and stent thrombosis (can be acute or later, with higher consequence).
Rehabilitation and functional recovery: participation in cardiac rehabilitation and gradual return to activity are commonly discussed after PCI, tailored to presentation (stable vs ACS) and overall risk.

Follow-up intervals and testing strategies vary by clinician and case. In general, routine invasive reassessment is not done without a clinical trigger; evaluation is commonly symptom-driven and may involve noninvasive stress testing or repeat angiography depending on the scenario.

Alternatives / comparisons

Choosing among coronary treatment strategies is individualized. Key comparisons include:

Bare Metal Stent vs drug-eluting stent (DES)
DES releases an antiproliferative drug to reduce neointimal hyperplasia and generally lowers restenosis risk compared with Bare Metal Stent.
DAPT duration considerations differ across guidelines, device generations, and bleeding risk profiles; current practice often uses DES broadly, including in patients considered for shorter DAPT, but this varies by clinician and case.
Both require careful implantation technique and attention to antiplatelet therapy to reduce thrombosis risk.
Bare Metal Stent vs balloon angioplasty alone
Balloon angioplasty avoids a permanent implant but has higher risks of elastic recoil and restenosis in many lesion types.
Stents provide scaffolding that stabilizes the lumen, but introduce implant-related risks (thrombosis, in-stent restenosis).
Bare Metal Stent vs optimized medical therapy
Medical therapy (antianginal agents, antiplatelets when indicated, lipid-lowering therapy, blood pressure management) treats ischemia and reduces atherosclerotic risk.
PCI primarily improves coronary blood flow at a focal lesion; symptom benefit and outcome impact depend on clinical context (stable ischemic heart disease vs ACS), anatomy, and patient risk.
Bare Metal Stent vs CABG
CABG is a surgical revascularization option often considered in complex multivessel disease, left main disease, diabetes with extensive CAD, or when complete revascularization by PCI is less feasible.
PCI with stenting is less invasive and has shorter initial recovery, while CABG may provide more durable revascularization in selected anatomic patterns; the balance varies by patient and anatomy.

Bare Metal Stent Common questions (FAQ)

Q: Is a Bare Metal Stent the same as a drug-eluting stent?
No. A Bare Metal Stent is a metal scaffold without a drug coating, while a drug-eluting stent releases medication intended to reduce tissue regrowth inside the stent. The choice between them depends on clinical context, bleeding risk, restenosis risk, and local practice.

Q: Does stent placement hurt?
During PCI, discomfort varies. Some people report chest pressure when the balloon is inflated, and access-site soreness can occur afterward. Pain experience depends on presentation, sedation strategy, and individual factors.

Q: What type of anesthesia is used for placing a Bare Metal Stent?
PCI is commonly performed with local anesthesia at the access site and conscious sedation, rather than general anesthesia. The exact approach varies by institution and patient stability, particularly in emergencies such as STEMI.

Q: How long does a Bare Metal Stent last?
The stent is intended to remain permanently in the artery. Clinical durability depends on healing response, restenosis development, stent sizing and expansion, and progression of atherosclerosis elsewhere. Some patients never need repeat treatment, while others may require re-intervention.

Q: What is the main long-term problem after a Bare Metal Stent?
A key issue is in-stent restenosis caused by neointimal hyperplasia. This may present as recurrent angina or ischemia during follow-up. Another serious but less common concern is stent thrombosis, which is closely tied to antiplatelet therapy and procedural factors.

Q: Will I need dual antiplatelet therapy (DAPT) after a Bare Metal Stent?
In general, antiplatelet therapy is required after any coronary stent to reduce thrombosis risk. The duration and specific regimen depend on the clinical scenario (stable vs ACS), bleeding risk, and contemporary guidelines, so it varies by clinician and case.

Q: Are there activity restrictions after Bare Metal Stent placement?
Short-term restrictions often relate to the vascular access site and overall recovery from the event (especially after myocardial infarction). Return to activity is typically gradual and individualized, and cardiac rehabilitation is often discussed. Specific timelines vary by clinician and case.

Q: How is follow-up monitored after a Bare Metal Stent?
Follow-up is usually symptom-focused and includes medication review and risk factor management. Additional testing (such as stress testing) may be used if symptoms recur or if there is concern for ischemia. Routine repeat angiography without symptoms is not standard in most settings.

Q: How does the cost of a Bare Metal Stent compare with other options?
Device costs vary by health system, payer structure, and local contracts. Bare Metal Stent devices have often been less expensive than some DES platforms, but overall episode-of-care cost also depends on follow-up needs and repeat procedures. Cost considerations are typically handled at the system level rather than at the bedside.

Q: If someone already has a Bare Metal Stent, can they later get a drug-eluting stent?
Yes, in some cases restenosis or new lesions can be treated with additional PCI using different devices, including DES. The strategy depends on angiographic findings, lesion location, and patient factors. Planning is individualized and may incorporate intravascular imaging to guide treatment.